Dalton Venture's Sun Qi: Dig Deep Into Your Own Track, and Wait for Your Own Market | Dalton Insights
Over the past year, TongDao's main focus areas have been three: brain-computer interfaces, bio-manufacturing, and new materials.
道彤投资
@daltonventure
以生命科学为根，向硬科技生长
88 articles
Articles
Racing to Compete in the Trillion-Dollar Blue Ocean of Bio-Manufacturing, Heart Capital's Bio-Manufacturing Fund Injects Strong Patient Capital into the Industry
Dalton Venture launched Shanghai's first bio-manufacturing industry fund, injecting strong patient capital into the sector.
Kongshan Ci Completes Series A Funding: Full-Stack Brain-Computer Neural Regulation Platform Leads New Paradigm in Psychiatric Diagnosis and Treatment | TongNews
Existing shareholder Dalton Venture continued to increase its stake.
Exclusive Interview with Professor Nie Zaiqing: Is the Biopharma Version of "AI Lobster" Here? Shuimu Molecular's Dual-Wheel Model of "Proprietary Pipeline + Tool Empowerment" | Tong's Family
An **AIR incubated company and Tongtou Family portfolio company**, **Shuimu Molecular** has emerged as one of the most promising benchmark enterprises in AI-driven drug discovery, pursuing a dual-engine strategy of "tool empowerment + proprietary pipeline development." Its core achievements include the ChatDD intelligent agent framework, the OpenBioMed open-source platform, Shuimu Zhiliao — a new consumer-facing "super brain" tool for life sciences — and multimodal large models.
Dalton Venture Selected as First-Batch Fund Manager for Hong Kong's Optimized Innovation and Technology Venture Fund Scheme
Leveraging a Hong Kong-based fund, DoTown deepens its cross-border innovation strategy bridging mainland China and the Greater Bay Area
Bangyun Medical Closes Nearly 100 Million Yuan Angel Round Led by Dalton Venture, Accelerating Upgrading and Global Innovation in Advanced Wound Closure | Dalton News
Dedicated to becoming a leading benchmark in China's domestic wound closure space.
On Day 5 of Brain-Computer Interface Treatment, a Depression Patient Brought a Lollipop... This Disruptive Therapy Could Win Approval Within a Year | Daotong Family
Minhang District Media Center has launched the "**Go, to the Lab**" series, going behind the scenes at Minhang's frontline research facilities to explore breakthrough technologies. This installment visits **a DaoTong portfolio company — KoSyne NeuroTech**.
Gestalt Tech Closes 150 Million Yuan Angel Round, Dalton Venture Co-Leads | Dalton News
Sets New Record for Largest Angel Round in China's Brain-Computer Interface Space
Mycowave Medical Completes Tens of Millions of RMB Angel Round, with Dalton Venture as Sole Investor, Expanding Non-Invasive Neuromodulation for Home and Diversified Scenarios | Dalton News
Recently, emerging neuromodulation company **MicroVention Medical Technology (Shanghai) Co., Ltd.** (abbreviated as "MicroVention Medical") announced the completion of a tens-of-millions-of-yuan angel funding round. The round was **exclusively invested by Dalton Venture**, marking the company's first external financing since its establishment in 2024.
KoSyne NeuroTech Completes Pre-A Round to Accelerate Clinical Translation of Brain-Computer Interface Neuromodulation Platform | Tong's Family
Recently, **KoSyne NeuroTech** (hereinafter referred to as "KoSyne NeuroTech"), a **Dongtou Family company** specializing in non-invasive brain-computer interfaces and neuromodulation, announced the completion of its **Pre-A funding round** — another key milestone following Dongtou Capital's exclusive angel round investment. **This round was led exclusively by Yunqi Capital, with the proceeds to be used primarily for core technology R&D, clinical translation, and global expansion.**